The total return over the past 12 months is -28.71% vs. +16.94% for the S&P 500. So far it's up +36.10% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (28.71%) | (26.99%) | (40.76%) | (15.75%) | N/A | N/A |
| Total Return CAGR | (28.71%) | (26.99%) | (40.76%) | (15.75%) | N/A | N/A |
| Revenue CAGR | +20.83% | +34.50% | (10.34%) | +23.59% | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Editas Medicine, Inc. (EDIT)
| Year | Start price | End price | EDIT Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $2.05 | $2.79 | +36.10% | +14.51% | +21.59% |
| 2025 | $1.27 | $2.05 | +61.42% | +17.72% | +43.70% |
| 2024 | $10.13 | $1.27 | (87.46%) | +24.89% | (112.35%) |
| 2023 | $8.87 | $10.13 | +14.21% | +26.19% | (11.98%) |
| 2022 | $26.55 | $8.87 | (66.59%) | (18.17%) | (48.42%) |
| 2021 | $70.11 | $26.55 | (62.13%) | +28.74% | (90.87%) |
| 2020 | $29.61 | $70.11 | +136.78% | +18.37% | +118.41% |
| 2019 | $22.75 | $29.61 | +30.15% | +31.22% | (1.07%) |
| 2018 | $30.73 | $22.75 | (25.97%) | (4.56%) | (21.41%) |
| 2017 | $16.23 | $30.73 | +89.34% | +21.70% | +67.64% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
